Belite Bio (BLTE) Stock Price, News & Analysis

Company Overview

Belite Bio, Inc. (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages. The company has established research collaborations with academic institutions and contract research organizations to advance its lead programs through regulatory milestones, emphasizing optimization of safety, efficacy and pharmacokinetic profiles to support future clinical trials.

Based in the United States, Belite Bio is led by a management team with extensive experience in biotechnology, drug development and regulatory affairs. The company’s strategic vision is to deliver innovative therapies for metabolic disorders with significant unmet medical needs and to pursue global clinical development to reach diverse patient populations.

Key Stats

• Today's Range: $73.00 to $74.25
• 50-Day Range: $59.67 to $73.00
• 52-Week Range: $43.70 to $86.53
• Volume: 72,658 shs
• Average Volume: 44,157 shs
• Market Capitalization: $2.33 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $96.00
• Consensus Rating: Moderate Buy

Belite Bio Stock Analysis - MarketRank™

Belite Bio scored higher than 58% of companies evaluated by MarketBeat, and ranked 576th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Belite Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Belite Bio has a consensus price target of $96.00, representing about 31.1% upside from its current price of $73.25.

Amount of Analyst Coverage

Belite Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Belite Bio are expected to grow in the coming year, from ($1.17) to ($0.83) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Belite Bio is -47.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Belite Bio is -47.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Belite Bio has a P/B Ratio of 15.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.65% of the float of Belite Bio has been sold short.

Short Interest Ratio / Days to Cover

Belite Bio has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Belite Bio has recently decreased by 4.65%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Belite Bio does not currently pay a dividend.

Dividend Growth

Belite Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.65% of the float of Belite Bio has been sold short.

Short Interest Ratio / Days to Cover

Belite Bio has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Belite Bio has recently decreased by 4.65%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.67

News Sentiment

Belite Bio has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Belite Bio this week, compared to 3 articles on an average week.

Search Interest

5 people have searched for BLTE on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Belite Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.53% of the stock of Belite Bio is held by institutions.

BLTE Stock Analysis - Frequently Asked Questions

How have BLTE shares performed this year?

Belite Bio's stock was trading at $63.10 on January 1st, 2025. Since then, BLTE shares have increased by 16.1% and is now trading at $73.25.

How were Belite Bio's earnings last quarter?

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) released its quarterly earnings results on Monday, August, 11th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.03.
Read the conference call transcript.

When did Belite Bio IPO?

Belite Bio (BLTE) raised $36 million in an initial public offering on Friday, April 29th 2022. The company issued 6,000,000 shares at $5.50-$6.50 per share.

Who are Belite Bio's major shareholders?

Top institutional investors of Belite Bio include Marshall Wace LLP (0.03%), JPMorgan Chase & Co. (0.02%), BNP Paribas Financial Markets (0.01%) and EverSource Wealth Advisors LLC (0.01%).

How do I buy shares of Belite Bio?

Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Belite Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Belite Bio investors own include Paycom Software (PAYC), Centrus Energy (LEU), Planet Labs PBC (PL), uniQure (QURE), Grayscale Ethereum Trust (ETH) (ETHE), Marathon Oil (MRO) and Vale (VALE).

Company Calendar

• Last Earnings: 8/11/2025
• Today: 9/18/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BLTE
• CIK: 1889109
• Web: belitebio.com
• Phone: 858-246-6240
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Belite Bio: $96.00
• High Price Target: $110.00
• Low Price Target: $80.00
• Potential Upside/Downside: +31.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.14 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -34.90%
• Return on Assets: -33.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 23.15
• Quick Ratio: 23.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.72 per share
• Price / Book: 15.52

Miscellaneous

• Outstanding Shares: 31,840,000
• Free Float: 27,607,000
• Market Cap: $2.33 billion
• Optionable: Not Optionable
• Beta: -1.50